Evidence map›Paper›PMID 33780499›Full record

ArticlePloS one2021

What do patients and dermatologists prefer regarding low-risk basal cell carcinoma follow-up care? A discrete choice experiment.

Sven van Egmond, Esther de Vries, Loes Hollestein, Maarten Bastiaens, Kees-Peter de Roos, Daniëlle Kuijpers, Ewout Steyerberg, Marlies Wakkee, Klara Mosterd, Tamar Nijsten and 1 more

Abstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sven van EgmondDepartment of Dermatology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.ORCID 0000-0002-1323-4928
Esther de VriesDepartment of Clinical Epidemiology and Biostatistics, Pontificia Universidad Javeriana, Hospital San Ignacio, Bogota, Colombia.ORCID 0000-0002-5560-2258
Loes HollesteinDepartment of Dermatology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Maarten BastiaensDepartment of Dermatology, TweeSteden Ziekenhuis, Tilburg, The Netherlands.
Kees-Peter de RoosDepartment of Dermatology, DermaPark, Uden, The Netherlands.ORCID 0000-0002-2970-8649
Daniëlle KuijpersDepartment of Dermatology, Amphia Ziekenhuis, Breda, The Netherlands.
Ewout SteyerbergDepartment of Public Health, Erasmus MC University Medical Center, Rotterdam, The Netherlands.ORCID 0000-0002-7787-0122
Marlies WakkeeDepartment of Dermatology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Klara MosterdDepartment of Dermatology, Maastricht University Medical Centre, Maastricht, The Netherlands.
Tamar NijstenDepartment of Dermatology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Esther W de Bekker-GrobSection of Health Technology Assessment & Erasmus Choice Modelling Centre, Erasmus School of Health Policy & Management, Erasmus University, Rotterdam, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFollow-up after low-risk basal cell carcinoma (BCC) is being provided more frequently than recommended by guidelines. To design an acceptable strategy to successfully reduce this 'low-value' care, it is important to obtain insights into the preferences of patients and dermatologists.

objectiveTo determine the preferences and needs of patients and dermatologists to reduce low-risk BCC follow-up care, and the trade-offs they are willing to make.

methodsA questionnaire including a discrete choice experiment was created, containing attributes regarding amount of follow-up, continuity of care, method of providing addition information, type of healthcare provider, duration of follow-up visits and skin examination. In total, 371 BCC patients and all Dutch dermatologists and dermatology residents (n = 620) were invited to complete the questionnaire. A panel latent class model was used for analysis.

resultsEighty-four dermatologists and 266 BCC patients (21% and 72% response rates respectively) completed the discrete choice experiment. If the post-treatment visit was performed by the same person as treatment provider and a hand-out was provided to patients containing personalised information, the acceptance of having no additional follow-up visits (i.e. following the guidelines) would increase from 55% to 77% by patients. Female patients and older dermatologists, however, are less willing to accept the guidelines and prefer additional follow-up visits. LIMITATIONS: The low response rate of dermatologists.

conclusionThis discrete choice experiment revealed a feasible strategy to substantially reduce costs, while maintaining quality of care, based on the preferences and needs of BCC patients, which is supported by dermatologists.

Indexed as

Basal Cell CarcinomaDermatologistsPatient PreferenceSkin NeoplasmsAdultAgedAged, 80 and overChoice BehaviorFemaleFollow-Up StudiesHumansMaleMiddle AgedNetherlandsSurveys and Questionnaires

Identifiers

PMID33780499
PMCPMC8007023

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.